Takeda shareholders give nod for $59 billion Shire acquisition

OSAKA (Reuters) – Takeda Pharmaceutical … “We are definitely against this because the financial risks are too great and the expected benefits are quite limited,” said Kazuhisa Takeda …
( read original story …)